Felix Biotechnology
DefunctYC W20San Francisco, US · Founded 2019 · 6 employees · 3 known investors
Felix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.
BiotechHealthtechGenomicsTherapeuticsUnited States of AmericaAmerica / CanadaPartly Remote
Founders & leadership· Y Combinator alumni (W20)
Felix Biotechnology was founded in 2019 by Robert McBride, Vivek Mutalik, and Paul Turner.
Investors · 3
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $484.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $314.4K |
| National Science Foundation | Phase I | 2021 | $256K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Felix Biotechnology do?
- Felix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.
- Who founded Felix Biotechnology?
- Felix Biotechnology was founded by Robert McBride, Vivek Mutalik, Paul Turner in 2019.
- Who are Felix Biotechnology's investors?
- Felix Biotechnology's investors include First In Ventures, Point72 Ventures, Y Combinator.
- Where is Felix Biotechnology headquartered?
- Felix Biotechnology is headquartered in San Francisco, US.